• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Baxter BioPharma Solutions

    Emergent BioSolutions

    Alcami

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Quotient Sciences

    Aphena Pharma Solutions

    Alcami

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    What Will Change at FDA for 2021?

    (R)evolution of the industry’s data, catalyzed by changes at FDA and what’s the likely impact to the pharmaceutical industry?

    What Will Change at FDA for 2021?
    Related CONTENT
    • Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate
    • Charles River Acquires Retrogenix
    • Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio
    • Eloxx Pharmaceuticals Acquires Zikani Therapeutics
    • Lonza Completes Divestment of Sites to NextPharma
    Ben Locwin, Contributing Editor, International COVID-19 Advisor, Healthcare Futurist04.01.21
    Typically, we assume that data exist whether or not we observe them. But HOW we observe situations to collect data inextricably changes the manner in which they are collected and where the analyses lead. This, ultimately, has a direct influence on the diseases and disorders which get focus and attention and which do not. As well, this principle influences which therapies gain a favorable evaluation by regulatory authorities, versus those that do not.

    This is all very important context to understand the FDA’s new Data Modernization Action Plan (DMAP), which is a framework for how it will handle, analyze, and respond to data which it receives.

    Janet Woodcock (acting Commissioner) and Amy Abernethy (acting Chief Information Officer) wrote, "Even small advances in our ability to gain useful insights from data can represent significant opportunities." I appreciate this perspective, because it suggests a deep truth, which is that there are larger unknown opportunities hidden in plain sight within our industry and its data, and improving how our data are collected and managed can elucidate some of these as-yet unknown mysteries.

    Ushering in any new framework within an international regulatory body always sets the industry alight with new activity, and the downstream changes as a result of DMAP will be no different. In addition, here are some other insights likely to occur over the next year as we move from ‘the new normal’ to ‘the pandemic that once was.’

    COVID-19 will stay at the top of the pyramid
    Therapies, preventives, and testing regimes for COVID-19 and its newer viral variants will continue to take the brunt of FDA’s resources throughout 2021, as the industry is still surging to fill niche and emergent needs within this space. Jeff Shuren, head of FDA’s CDRH division, sees 2021 as a year to ‘reset’ by looking at COVID-19 technologies, but also approaches that are not coronavirus-related.

    In my estimation, the idea of tracking epidemiology of viral variants, such as B.1.1.7, P.1, P.2, B.1351 (or 20H/501Y.V2), etc., will be ongoing and will lead to some competitors working in the booster vaccine space for annual or semi-annual variant-boosters.

    Enforcement changes
    As Heraclitus of Ephesus said about 2,500 years ago, “Change is the only constant.” And he’s still right.* We’ve seen enforcement actions ebb and flow across the industry over the past many decades. In the last 5 years in medical devices, for example, enforcement actions vis-à-vis FDA Warning Letters dropped by almost 90%. In 2020, FDA put a halt to onsite inspections in a statement dated 18Mar20 titled, “FDA Focuses on Safety of Regulated Products While Scaling Back Domestic Inspections.” It was determined to handle inspections on a case-by-case basis, and while some domestic facility inspections resumed by the end of last summer, there is still a significant backlog to winnow down in terms of site visits and ensuing enforcement actions.

    This will have a variable approach applied across pharma and med devices, because for example, IMDRF's Medical Device Single Audit Program (MDSAP) is now in-process, and the FDA is a participating member. This would allow the FDA to satisfy their requirement for a facility audit via another MDSAP-recognized auditing organization having done so as a proxy. The FDA has said it will accept MDSAP audit reports as a "substitute" for routine agency inspections.

    Tl;dr: There will be more inspections ramping up throughout 2021 and beyond, wherein the regulatory pendulum is likely to swing to the other direction from where it has been more recently.

    Digital Health Center of Excellence
    Intended to provide "efficient and least burdensome oversight" while meeting "standards for safe and effective products," the FDA is into Year One of this nascent initiative.
    Though there has been a clinical decision support (CDS) software guidance in draft since September 2019, there hasn’t yet been a finalized version. This, along with the FDA’s approaches to Software as a Medical Device (SaMD), are likely to be finalized relatively soon.

    Much ado about algorithmic opacity
    As you can imagine, this is a difficult set of documents to draft and refine, which may not actually be evident at the outset. These guidances will usher in the future of when more clinical decisions are offloaded to artificial intelligence and machine learning (AI/ML) instead of clinicians, and also how AI/ML algorithms will make decisions as part of medical devices as well. How these are initially written will help define what the future will look like, so they are not guidance documents to take lightly.

    There is still the looming reality that machine learning and deep learning (DL) algorithms are supposed to—by their very design and functionality—continually evolve. This very black-box nature of how they do what they do is what seems to, in my estimation, put many of them in violation of 2 specific articles of GDPR, the EU’s data protection regulation. The FDA has so far only approved medical devices that have used locked algorithms that cannot change.

    In evaluating AI/ML/DL algorithms in the context of clinical studies, my compliance concerns are what led me, along with some others about 5 years ago, to coin the term ‘algorithmic opacity,’ for it is not easy—and indeed, sometimes not possible—to divine what the algorithm is actually doing to come up with the decisions that it does (much more to come on this aspect). We’re on a collision course with inevitability here in our data-rich healthcare future.

    The future of the industry, and ‘futuristics’
    Looking ahead, it’s important to note that life will begin to reopen globally, even if some days it doesn’t seem like it. Some regions (e.g., Australia) don’t even really have an endemic COVID-19 situation anymore, which will change once travel re-opens in earnest—and ‘temperature checks’ won’t help and have never helped in this regard. But we’ve all gotten better at adapting to changing environments.

    At any rate, those things which could occur—or may not occur—in the industry are ‘futuristics’: All the set of variables which conspire constructively and destructively to eliminate some possible future timelines, and augment others.

    As we see how the public behaves on a population scale with vaccination administration and personal freedoms, we’ll garner new opportunities, and others will be closed off from us. Social media in this regard has proved to continue to be our worst enemy. By giving a voice to nonscientific and fraudulent claims by laypeople, conspiratorial threads can be woven and build up momentum to virality. What those who develop these narratives don’t understand is that, on a grand scale, real psychological and physical harms come from these cynical contrarian and divisive viewpoints, and the confusion sown doesn’t actually help anyone—except the ever-increasing ticker of ‘Likes’ from their posts. #Fact. 

    *End note: Most of the reason that Heraclitus is still right is because of the Second Law of Thermodynamics, the concept of entropy, and nature trying to reach equilibrium. Because entropy tends to increase to a maximum, this brings with it change.


    Ben Locwin
    Contributing Editor, International COVID-19 Advisor, Healthcare Futurist

    Having spent the past 14 months performing state and national epidemiology of the pandemic, working on vaccine candidates, and developing public health policies, Ben is optimistically looking-ahead to a more freedom-rich future. He has been writing the Clinically Speaking column for seven years; this is about 60% of the orbital period of the planet Jupiter (12 years). In some circles, there is a notion that all the cells in your body are replaced every 7 years. This, however, is scientific rubbish. Cell turnover is continuous and highly variable. Stay safe out there, get vaccinated.
    Related Searches
    • Biologics, Proteins, Vaccines
    Suggested For You
    Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate
    Charles River Acquires Retrogenix Charles River Acquires Retrogenix
    Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio
    Eloxx Pharmaceuticals Acquires Zikani Therapeutics Eloxx Pharmaceuticals Acquires Zikani Therapeutics
    Lonza Completes Divestment of Sites to NextPharma Lonza Completes Divestment of Sites to NextPharma
    NEOCERAM NEOCERAM
    CureVac, Celonic Enter COVID-19 Vax Mfg. Pact CureVac, Celonic Enter COVID-19 Vax Mfg. Pact
    KD Pharma Acquires Rohner AG Manufacturing Assets KD Pharma Acquires Rohner AG Manufacturing Assets
    mAbxience Bolsters Biosimilar and CDMO Manufacturing Capacity mAbxience Bolsters Biosimilar and CDMO Manufacturing Capacity
    PPD, Clinical Ink Partner on Near Real-Time Access to Endpoint Data PPD, Clinical Ink Partner on Near Real-Time Access to Endpoint Data
    Thermo Fischer Scientific Collaborates with Protein Metrics Thermo Fischer Scientific Collaborates with Protein Metrics
    Fujifilm Selects North Carolina for $2B Bio CDMO Facility Fujifilm Selects North Carolina for $2B Bio CDMO Facility
    Alcami Names Patrick D. Walsh as Chairman and CEO Alcami Names Patrick D. Walsh as Chairman and CEO
    SpyBiotech Licenses Selexis’ SUREtechnology for HCMV Vax SpyBiotech Licenses Selexis’ SUREtechnology for HCMV Vax
    Romaco Acquires STE Tecpharm Romaco Acquires STE Tecpharm

    Related Columns

    • Biologics, Proteins, Vaccines
      Vaccines and Return-To-Normalcy

      Vaccines and Return-To-Normalcy

      Planning for a future in which COVID-19 won’t simply ‘disappear.’
      Ben Locwin, Contributing Editor 03.01.21

    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20


    • Biologics, Proteins, Vaccines
      Outsourcing in China: How far can it go?

      Outsourcing in China: How far can it go?

      China’s biopharmaceutical services market is on pace to top $1 billion by 2021
      Vicky Qing Xia, BioPlan Associates 07.15.19

    • Biologics, Proteins, Vaccines | Drug Development
      The Future Is… Therapeutic

      The Future Is… Therapeutic

      As cell and gene therapies rise, so too does outsourcing
      Ben Locwin 06.13.19

    • Biologics, Proteins, Vaccines
      Innovate UK Grant Supports Viral Vector Manufacturing

      Innovate UK Grant Supports Viral Vector Manufacturing

      Cobra Biologics talks about its recently awarded $3.4 million capital infrastructure investment
      Betsy Louda, Associate Editor 04.10.18


    • Biologics, Proteins, Vaccines | Injectables
      A World of Innovation

      A World of Innovation

      The importance of innovation in the injectable business and the hurdles a CDMO faces
      Claudia Roth, Vetter Pharma-Fertigung GmbH & Co. KG 11.07.17

    • Biologics, Proteins, Vaccines
      India is an Emerging Hub  For Low-cost Vaccines

      India is an Emerging Hub For Low-cost Vaccines

      Improvising basic vaccines to enhance stability, efficacy and compliance
      S. Harachand, Contributing Editor 11.07.17

    • Biologics, Proteins, Vaccines
      Flu Season is Upon Us

      Flu Season is Upon Us

      My chance and capricious Monday afternoon run-in with antiscience nonsense
      Ben Locwin, Contributing Editor 11.07.17


    • Biologics, Proteins, Vaccines
      Trends in New Technologies & Budgets

      Trends in New Technologies & Budgets

      Budget increases in biopharmaceutical industry indicate future growth
      Eric S. Langer, BioPlan Associates 06.06.17

    • Biologics, Proteins, Vaccines

      Biomanufacturing Trends and Outlook 2017: Where Is It All Going?

      A look at the technological advances permeating (bio)pharma manufacturing
      Ben Locwin, Contributing Editor 04.20.17

    • Biologics, Proteins, Vaccines
      CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges

      CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges

      Technically trained staff needed to run complex manufacturing platforms, automation
      Eric S. Langer, BioPlan Associates 03.07.17


    • Biologics, Proteins, Vaccines

      Year-End Trends in Biopharma Contract Manufacturing

      Budgets are flattening, but some CMOs are well positioned for growth
      Eric S. Langer, BioPlan Associates 11.09.16

    • Biologics, Proteins, Vaccines

      Economics of In-House Buffer Preparation

      Evaluating the cost effectiveness of keeping basic ops in-house
      Eric S. Langer, BioPlan Associates 09.08.16

    • Biologics, Proteins, Vaccines | cGMP Manufacture | GMPs/GCPs | Preclinical Outsourcing | Process Development | Risk Management

      Getting to Yes

      The critical attributes CMOs need to demonstrate to win business
      Eric S. Langer, BioPlan Associates 07.14.15

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Alkermes, Merck Enter Clinical Trial And Supply Agreement
    • Ascendia Pharmaceuticals Poised For Expansion
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Chromaflo Technologies Awarded Gold Status CSR Rating by EcoVadis in EMEA
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands 'Beautiful' Fagrance Collection
    Mushrooms Are Key Ingredients in Beauty & Wellness
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login